Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids

Executive Summary

FDA's complete response letter includes extensive list of new studies needed to support abuse-deterrence claims not featured in two prior CRLs, Pain Therapeutics says, wondering why the agency is only now raising issues that could have been discussed previously.

Advertisement

Related Content

Opioid Warning Letter To Cipher Likely Easy Call For US FDA
Black Box 'Best Case' Hopes On Vaginal Estradiol Dashed For TherapeuticsMD
Keeping Track: US FDA Clears Three Novel Agents Over Three Days – Bavencio, Symproic And Xadago
Pain Therapeutics Confident It Has US Approval Pathway Set For Remoxy ER
FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized
US FDA Review Management Challenged After Spate Of Complete Response Letters
FDA’s Promotional Enforcement Still Playing It Safe
FDA's Drug Promotion Advisory Reviews Taking Longer
KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence
Pain's Remoxy Skips Over Panel On Rocky Road To Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119241

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel